APA (7th ed.) Citation

TO, C., BT, D., JW, D., S, D. Y., T, D., LL, N., . . . Y, C. (2024). Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study. Neurology, 102(5), e209151. https://doi.org/10.1212/WNL.0000000000209151

Chicago Style (17th ed.) Citation

TO, Crawford, et al. "Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study." Neurology 102, no. 5 (2024): e209151. https://doi.org/10.1212/WNL.0000000000209151.

MLA (9th ed.) Citation

TO, Crawford, et al. "Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study." Neurology, vol. 102, no. 5, 2024, p. e209151, https://doi.org/10.1212/WNL.0000000000209151.